Systems announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU ...

The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system for use with a commercialized ...

KORU Medical Systems, Inc. ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric ...

The SCIg market is growing rapidly, with KORU Medical Systems outperforming competitors by capturing market share. Read why I ...

Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.